A Multicentric, Open-label, Non-randomized, Pharmacokinetic and Tolerability Study of Fexinidazole Given as an Oral Single 1200 mg Dose in Participants With Mild and Moderate Hepatic Impairment, and in Matched Participants With Normal Hepatic Function
Latest Information Update: 12 Jun 2023
At a glance
- Drugs Fexinidazole (Primary)
- Indications African trypanosomiasis; Chagas disease
- Focus Pharmacokinetics
- Sponsors Sanofi
- 19 Apr 2023 Planned End Date changed from 21 Apr 2023 to 27 Apr 2023.
- 19 Apr 2023 Planned primary completion date changed from 21 Apr 2023 to 27 Apr 2023.
- 19 Apr 2023 Status changed from recruiting to active, no longer recruiting.